ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 238 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,680 | +74.0% | 2,000 | +100.0% | 0.00% | 0.0% |
| Q2 2023 | $23,950 | +27.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $18,820 | +18.2% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $15,920 | -0.5% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $16,000 | +14.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $14,000 | -41.7% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $24,000 | +4.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $23,000 | -8.0% | 1,000 | -33.7% | 0.00% | 0.0% |
| Q3 2021 | $25,000 | -32.4% | 1,508 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $37,000 | -5.1% | 1,508 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $39,000 | -51.9% | 1,508 | 0.0% | 0.00% | -57.1% |
| Q4 2020 | $81,000 | +30.6% | 1,508 | 0.0% | 0.01% | 0.0% |
| Q3 2020 | $62,000 | +158.3% | 1,508 | +201.6% | 0.01% | +133.3% |
| Q2 2020 | $24,000 | +14.3% | 500 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $21,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
| SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
| HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
| Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
| GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
| EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
| Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
| Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
| ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |